Skip to main content Accessibility help

Nosocomially Acquired Pseudomonas cepacia Infection in Patients with Cystic Fibrosis

  • Ofelia C. Tablan (a1)
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Nosocomially Acquired Pseudomonas cepacia Infection in Patients with Cystic Fibrosis
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Nosocomially Acquired Pseudomonas cepacia Infection in Patients with Cystic Fibrosis
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Nosocomially Acquired Pseudomonas cepacia Infection in Patients with Cystic Fibrosis
      Available formats


  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.


Corresponding author

Centers for Disease Control and Prevention, Investigation and Prevention Branch, 1600 Clifton Rd., NE, Bldg. 3, Rm. B-49, Mailstop A-07, Atlanta, GA 30333


Hide All
1.Isles, A, Maclusky, I, Corey, M, et al. Pseudomonas cepacia infection in cystic fibrosis patients: an emerging problem. J Pediatr. 1984;104:206210.
2.Thomassen, MJ, Demko, CA, Klinger, JD, Stern, RC. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Hespir Dis. 1985;131:791796.
3.Tablan, OC, Chorba, TL, Schidlow, DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: Risk factors and clinical outcome. J Pediatr. 1985;107:382387.
4.Simmonds, EJ, Conway, SP, Ghoneim, ATM, Ross, H, Littlewood, JM. Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child. 1990;655:874877.
5.Gladman, G, Connor, PJ, Williams, RF, David, TJ. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child. 1992;67:192195.
6.Govan, JRW, Glass, S. The microbiology and therapy of cystic fibrosis lung infections. Rev Med Microbiol. 1990;1:1928.
7.Corey, M, Allison, L, Prober, C, et al. Sputum bacteriology in patients with cystic fibrosis in a Toronto hospital during 1970-1981. J Infect Dis. 1984;149:283.
8.Saijan, US, Corey, M, Karmali, MA, Forstner, JEBinding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Investig. 1992;89:648656.
9.Tablan, OC, Martone, WJ, Doershuk, CF, et al. Risk factors an outcome associated with Pseudomonas cepacia colonization of the respiratory tract of patients with cystic fibrosis. Chest. 1987;91:527533.
10.Tablan, OC, Carson, LA, Cusick, LB, Bland, LA, Martone, WJ. Use of selective media in isolating Pseudomonas cepacia from simulated sputum specimens of cystic fibrosis patients: Results of laboratory proficiency tests. J Clin Microbial. 1987;25:485487.
11.Hardy, KA, McGowan, KL, Fischer, MC, Schidlow, DV. Pseudomoms cepacia in the hospital setting: Lack of transmission between cystic fibrosis patients. J Pediatr. 1986;109:5154.
12.Gessner, AR, Mortensen, JE. Pathogenic factors of Pseudomonas cepacia isolates from patients with cystic fibrosis. J Med Microbiol. 1990;33:115120.
13.LiPuma, JJ, Mortensen, JE, Dasen, SE, et al. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pediatr. 1988;113:859862.
14.LiPuma, JJ, Fisher, K, Dasen, SE, Mortensen, JE, Stall, TL. Ribotype stability of serial pulmonary isolates of Pseudomonas cepacia. J Infect Dis. 1991;164:133136.
15. Fitzsimmons SA Personal communication with author. Also unpublished date from the Centers for Disease Control and Prevention, Atlanta, GA.
16.Hoiby, N. Microbiology of lung infections in cystic fibrosis patients. Acta Faediatr Scand. 1982;301 (Suppl):3354.
17.Hoiby, N, Flensborg, EW, Beck, B, Friis, B, Jacobsen, JV, Jacobsen, L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed Immunoelectrophoresis. Scand J Respir Dis. 1977;58:6579.
18.Pitcher-Wilmott, RW, Levinsky, RJ, Gordon, I, Turner, MW, Matthew, DJ. Pseudomonas infection, allergy, and cystic fibrosis. Arch Dis Child. 1982;57:582586.
19.Baltimore, RS, Christie, CDC, Smith, GIW. Immunologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Am Rev Respir Dis. 1989;140:16501661.
20.Knohe, JD, Stern, RC, Doershuk, CF, Boat, TF, Matthews, LW. Cystic fibrosis: the prognosis for five year survival. Pediatr Res. 1978;12:676679.
21.Wilmott, RW, Tyson, SL, Matthew, DJ. Cystic fibrosis survival rates. The influences of allergy and Pseudomonas aeruginosa. Am J Dis Child. 1985;139:669671.
22.Henry, RL, Mellis, CM, Petrovic, L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Fediatr Pulmonol. 1992;12:158161.
23.Conly, JM, Klass, LL, Larson, L, Kennedy, J, Low, DE, Harding, GKM. Pseudomonas cepacia colonization and infection in intensive care units. Can Med Assoc J. 1986;134:363366.
24.Gelbart, SM, Reinhardt, GEGreenlee, HB. Pseudomonas cepacia strains isolated from water reservoirs of unheated nebulizers. J Clin Microbiol. 1976;3:6266.
25.Grieble, HG, Colton, RF, Bird, TJ, Toigo, A, Griffith, LG. Fine particle humidifiers: source of Pseudomonas aeruginosa infections in a respiratory disease unit. N Engl J Med. 1970;282:531535.
26.Martone, WJ, Tablan, OC, Jarvis, WR. The epidemiology of nosocomial epidemic Pseudomonas cepacia infections. Eur J Epidemiol. 1987;3:222232.
27.Martone, WJ, Osterman, CA, Fisher, KA, et al. Pseudomonas cepacia: implications and control of epidemic nosocomial colonization. Rev Infect Dis. 1981;3:708715.
28.Stover, GB, Drake, DR, Montie, TC. Virulence of different pseudomonas species in a burned mouse model: tissue colonization by Pseudomonas cepacia. Infect Immun. 1983;41:10991104.
29.Nakazawa, T, Yamada, Y, Ishibashi, M. Characterization of hemolysin in extracellular products of Pseudomonas cepacia. J Clin Microbiol. 1984;19:291293.
30.McKevitt, AL, Woods, DE. Charcterization of Pseudomonas cepacia isolates from patients with cystic fibrosis. J Clin Microbiol. 1984;19:291293.
31.Vasil, ML, Krieg, DP, Kuhns, JS, et al. Molecular analysis of hemolytic and phospholipase C activities of Pseudomonas cepacia. Infect Immun. 1990;58:40204029.
32.Rosenstein, BJ, Hall, DE. Pneumonia and septicemia due to Pseudomonas cepacia in a patient with cystic fibrosis. Johns Hopkins Med J. 1980;47:188189.
33.Boxerbaum, JF, Klinger, JD. Pseudomonas cepacia bacteremia in cystic fibrosis. Pediatr Res. 1984;18:269A.
34.Tomashefski, JF, Thomassen, Ml. Bruce, MC. Goldberg, HI, Konstan, MW, Stern, RC. Pseudomonas cepacia-associated pneumonia in cystic fibrosis. Relation of clinical features to histopathologic patterns of pneumonia. Arch Pathol Lab Med. 1988;112:166172.
35.Gold, R, Jim, E, Levison, H, et alCeftazidime alone and in combination in patients with cystic fibrosis: Lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother. 1983;12(supp A):331336.
36.Fass, RJ, Bamishan, J. In vitro susceptibility of nonfermentative gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents. Rev Infect Dis. 1980;2:841843(abstract).
37.Klinger, JD, Thomassen, MJ. Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis. 1985;3:149158.
38.Thomassen, MJ, Demko, CA, Doershuk, CEStern, RC, Klinger, JD. Pseudomonas cepacia: Decrease in colonization in cystic fibrosis patients. Am Rev Respir Dis. 1986;134:669671.
39.Millar-Jones, L, Paull, A, Saunders, Z, Goodchild, MC. Transmission of Pseudomonas cepacia among cystic fibrosis patients. Lancet. 1992;340:491.
40.Johanson, WG, Pierce, AK, Sanford, JP. Changing pharyngeal bacterial flora of hospitalized patients. N Engl J Med. 1969;281:11371140.
41.Pegues, DA. Personal communication with author.
42.Johanson, WG, Pierce, AK, Sanford, JP, Thomas, GD. Nosocomial respiratory infections with gram-negati ve bacilli. Ann Intern Med. 1972;77:701706.
43.Craven, DE, Kunches, LM, Kilinsky, V, Lichtenberg, DA, Make, BJ, McCabe, WR. Risk factors for pneumonia and fatality in natients receiving continuous mechanical ventilation. Am Rev Respir Dis. 1986;133:792796.
44.Weinstein, RA, Kabins, SA. Strategies for prevention and control of multiple drug-resistant nosocomial infection. Am J Med. 1981;70:449454.
45.Casewell, M, Phillips, I. Hands as route of transmission for Klebsiella species. Brit Medf. 1977;2:13151317.
46.Tummler, B, Koopman, U, Frothues, D, Weissbredt, H, Steinkamp, G. Hardt, H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol. 1991;29:12651267.
47.LiPuma, JJ, Dasen, TD, Nielson, DW, Stern, RC, Stull, TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990:10941096.
48.Nelson, JW, Doherty, CJBrown, PH, et al. Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet. 1991;338:1525.
49.Garner, JS, Simmons, BPGuideline for isolation precautions in hospitals. Infect Control. 1983;4(supp):245325.
50.Tablan, OC, Martone, WJ, Jarvis, WR. The epidemiology of Pseudomonas cepacia inpatients with cystic fibrosis. Eur J Epidemiol. 1987;3:336342.
51.Conly, JM, Hill, S, Ross, J, Lertzman, J, Louie, TJ. Handwashing practices in an intensive care unit: The effects of an educational program and its relationship to infection rates. Am J Infect Control. 1989;17:330339.
52.Rabkin, CS, Jarvis, WR, Anderson, RL, et al. Pseudomonas cepacia typing systems: collaborative study to assess their potential in epidemiologic investigations. Rev Infect Dis. 1989;11:600607.
53.Anderson, DJ, Kuhns, JS, Vasil, ML, Gerding, DN, Janoff, EN. DNA fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas cepaciu isolates from a nosocomial outbreak. J Clin Microbiol. 1991;29:648649.
54.Pierce, AK, Sanford, JP. Bacterial contamination of aerosols. Arch Intern Med. 1973;131:156159.
55.Kuhn, RJ, Lubin, AH, Jones, PR, et alBacterial contamination of aerosol solutions used to treat cystic fibrosis. Am J Hasp Pharm. 1982;39:308309.
56.Reinarz, JA, Pierce, AK, Mays, BB, Sanford, JRThe potential role of inhalation therapy equipment in nosocomial pulmonary infection. J Clin Investig. 1965;44:831839.
57.Pierce, AK, Sanford, JP, Thomas, GD, Leonard, JS. Long-term evaluation of decontamination of inhalation-therapy equipment and the occurrence of necrotizing pneumonia. N Engl J Med. 1970;292:528531.
58.Simmons, BPWong, ES. Guideline for prevention of nosocomial pneumonia. Infect Control. 1982;3:327333.
59.Garner, JS, Favero, MS. Guideline for handwashing and hospital enviromental control. Infect Control. 1986;7:231242.

Nosocomially Acquired Pseudomonas cepacia Infection in Patients with Cystic Fibrosis

  • Ofelia C. Tablan (a1)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.